 | Up a level |
2019
Younes, Anas, Sehn, Laurie H., Johnson, Peter 
ORCID: 0000-0003-2306-4974, Zinzani, Pier Luigi, Hong, Xiaonan, Zhu, Jun, Patti, Caterina, Belada, David ORCID: 0000-0002-4981-6188, Samoilova, Olga, Suh, Cheolwon, Leppae, Sirpa, Rai, Shinya, Turgut, Mehmet, Jurczak, Wojciech ORCID: 0000-0003-1879-8084, Cheung, Matthew C., Gurion, Ronit, Yeh, Su-Peng, Lopez-Hernandez, Andres, Duehrsen, Ulrich, Thieblemont, Catherine, Chiattone, Carlos Sergio, Balasubramanian, Sriram, Carey, Jodi, Liu, Grace, Shreeve, S. Martin, Sun, Steven, Zhuang, Sen Hong, Vermeulen, Jessica, Staudt, Louis M., Wilson, Wyndham, Fisher, Richard I., Engert, Andreas, Stadtmauer, Edward A. and Wei, Lee-Jen
(2019).
Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.
J. Clin. Oncol., 37 (15).
S. 1285 - 1307.
ALEXANDRIA:
AMER SOC CLINICAL ONCOLOGY.
ISSN 1527-7755
2015
Hallek, Michael, Kay, Neil E., Osterborg, Anders, Chanan-Khan, Asher A., Mahler, Michelle, Salman, Mariya, Wan, Ying, Sun, Steven, Zhuang, Sen Hong and Howes, Angela (2015). The HELIOS trial protocol: a Phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia. Future Oncol., 11 (1). S. 51 - 60. LONDON: FUTURE MEDICINE LTD. ISSN 1744-8301